Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myozenin-1 (MYOZ1, also known as calsarcin-2) is a Z-disc structural and adapter protein highly expressed in skeletal muscle and to a lesser extent in cardiac tissue[1][3][5]. It binds multiple Z-disc proteins, including α-actinin, γ-filamin, and telethonin, and colocalizes at the sarcomeric Z-line, serving as a molecular hub that stabilizes and organizes the contractile apparatus[1][2][4][5]. MYOZ1 also interacts with calcineurin, modulating its activity and thereby regulating the calcineurin/NFAT signaling pathway important for muscle fiber type differentiation and muscle growth[3][5]. Mutations in the MYOZ1 gene have been linked to various myopathies and cardiac hypertrophy, but do not appear to be major drivers of idiopathic dilated cardiomyopathy[1][3][5]. While MYOZ1 has clear biological roles in muscle structure and function, it is not considered a receptor, enzyme, transporter, or direct therapeutic target at present.
Null (as MYOZ1 is not a therapeutic target for drugs)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myozenin-1 (MYOZ1).